SSTR2 and adenoma: Lim and Fleseriu (2022) further emphasized that factors such as sparsely granulated adenomas, low SSTR2 status, and genetic mutations can predict resistance to first-generation SSAs, suggesting these patients might be better candidates for pegvisomant or pasireotide treatment (26).